NLRP1 and cancer: Through a systematic in silico study, we observed NLRP1 dysregulation in multiple tumor types, with significant correlations to survival outcomes, cancer‐associated fibroblast infiltration, and drug sensitivity, highlighting its potential as a biomarker for cancer diagnosis, prognosis, and personalized treatment strategies.